Template:Sulfadiazine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 7: Line 7:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine microbiology|Microbiology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine indications and usage|Indications and Usage]]
Line 17: Line 15:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine adverse reactions|Adverse Reactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine adverse reactions|Adverse Reactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine overdosage|Overdosage]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Sulfadiazine dosage and administration|Dosage and Administration]]

Latest revision as of 08:24, 9 January 2014